title: Clinical manifestations and treatment of Churg-Strauss syndrome.
abstract: Churg-Strauss syndrome (CSS) is a systemic necrotizing vasculitis affecting small to medium-sized vessels, and characterized by asthma, blood hypereosinophilia, and eosinophil-rich granulomatous inflammation of the respiratory tract. In the past few years the pathogenesis of the disease and its clinical manifestations have been clarified, fostering important advances in the treatment of CSS. Systemic corticosteroids are still considered the cornerstone of treatment. Many issues need to be addressed, such as how to maintain remission, prevent disease relapses, and treat refractory disease. This review provides a clinical overview of CSS and a summary of the current treatments and novel therapies.
authors.affiliation: Rheumatology Unit, Department of Internal Medicine, University of Pisa, 56126 Pisa, Italy.
authors.forename: Chiara
authors.initials: C
authors.lastname: Baldini
authors.forename: Rosaria
authors.initials: R
authors.lastname: Talarico
authors.forename: Alessandra
authors.initials: A
authors.lastname: Della Rossa
authors.forename: Stefano
authors.initials: S
authors.lastname: Bombardieri
mesh_terms: D000305:Adrenal Cortex Hormones / Q000008:administration & dosage; D019268:Antibodies, Antineutrophil Cytoplasmic / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001249:Asthma / Q000150:complications / Q000276:immunology; D015267:Churg-Strauss Syndrome / Q000150:complications / Q000188:drug therapy / Q000276:immunology*; D004359:Drug Therapy, Combination; D004802:Eosinophilia / Q000150:complications / Q000188:drug therapy / Q000276:immunology; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D012074:Remission Induction
chemical_list: D000305:Adrenal Cortex Hormones; D019268:Antibodies, Antineutrophil Cytoplasmic; D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D007166:Immunosuppressive Agents